Summit Therapeutics Says Partner Akeso Receives Third China NMPA Approval For Ivonescimab, Covering First-Line Advanced Squamous NSCLC With Chemotherapy

Loading news article.

Summit Therapeutics Says Partner Akeso Receives Third China NMPA Approval For Ivonescimab, Covering First-Line Advanced Squamous NSCLC With Chemotherapy | WAPE

Summit Therapeutics Says Partner Akeso Receives Third China NMPA Approval For Ivonescimab, Covering First-Line Advanced Squamous NSCLC With Chemotherapy

Article summary

Related companies

Comments —